Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1988 Sep;65(1):87–92.

Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden.

M Awwad 1, R J North 1
PMCID: PMC1385024  PMID: 2972604

Abstract

A cyclophosphamide (Cy)-resistant immunogenic tumour, the L5178Y lymphoma, was used to demonstrate that Cy-treatment of a host bearing this tumour enables passively transferred tumour-sensitized T cells to cause complete tumour regression without any need for Cy to cause a reduction in tumour burden. It was shown that whereas infusion of tumour-sensitized T cells from immune donors had very little effect on growth of the tumour, and whereas treatment with 150 mg/kg of Cy caused appreciable enhancement of tumour growth, combination therapy with Cy plus immune T cells caused complete tumour regression and resulted in long-term survival. Evidence that Cy treatment facilitated the expression of adoptive immunity against the L5178Y lymphoma by eliminating tumour-induced suppressor T cells consisted of the demonstration that tumour regression caused by combination treatment with Cy and immune T cells could be inhibited by infusing the recipient with Cy-sensitive, L3T4+ T cells from tumour-bearing but not from normal donors.

Full text

PDF
87

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Askenase P. W., Hayden B. J., Gershon R. K. Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J Exp Med. 1975 Mar 1;141(3):697–702. doi: 10.1084/jem.141.3.697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berendt M. J., North R. J. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med. 1980 Jan 1;151(1):69–80. doi: 10.1084/jem.151.1.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bonventre P. F., Nickol A. D., Ball E. J., Michael J. G., Bubel H. C. Development of protective immunity against bacterial and viral infections in tumor-bearing mice coincident with suppression of tumor immunity. J Reticuloendothel Soc. 1982 Jul;32(1):25–35. [PubMed] [Google Scholar]
  4. Bookman M. A., Swerdlow R., Matis L. A. Adoptive chemoimmunotherapy of murine leukemia with helper T lymphocyte clones. J Immunol. 1987 Nov 1;139(9):3166–3170. [PubMed] [Google Scholar]
  5. Claman H. N., Miller S. D., Conlon P. J., Moorhead J. W. Control of experimental contact sensitivity. Adv Immunol. 1980;30:121–157. doi: 10.1016/s0065-2776(08)60195-9. [DOI] [PubMed] [Google Scholar]
  6. Dye E. S., North R. J. Adoptive immunization against an established tumor with cytolytic versus memory T cells. Immediate versus delayed onset of regression. Transplantation. 1984 Jun;37(6):600–605. doi: 10.1097/00007890-198406000-00015. [DOI] [PubMed] [Google Scholar]
  7. Dye E. S., North R. J., Mills C. D. Mechanisms of anti-tumor action of Corynebacterium parvum. I. Potentiated tumor-specific immunity and its therapeutic limitations. J Exp Med. 1981 Sep 1;154(3):609–620. doi: 10.1084/jem.154.3.609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Evans R. Combination therapy by using cyclophosphamide and tumor-sensitized lymphocytes: a possible mechanism of action. J Immunol. 1983 Jun;130(6):2511–2513. [PubMed] [Google Scholar]
  9. Goto M., Mitsuoka A., Sugiyama M., Kitano M. Enhancement of delayed hypersensitivity reaction with varieties of anti-cancer drugs. A common biological phenomenon. J Exp Med. 1981 Jul 1;154(1):204–209. doi: 10.1084/jem.154.1.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Greenberg P. D., Cheever M. A. Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells. J Immunol. 1984 Dec;133(6):3401–3407. [PubMed] [Google Scholar]
  11. Greene M. I. The genetic and cellular basis of regulation of the immune response to tumor antigens. Contemp Top Immunobiol. 1980;11:81–116. doi: 10.1007/978-1-4684-3701-0_2. [DOI] [PubMed] [Google Scholar]
  12. Hall B. M., Jelbart M. E., Gurley K. E., Dorsch S. E. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Mediation of specific suppression by T helper/inducer cells. J Exp Med. 1985 Nov 1;162(5):1683–1694. doi: 10.1084/jem.162.5.1683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hellström K. E., Hellström I. Cellular immunity against tumor antigens. Adv Cancer Res. 1969;12:167–223. doi: 10.1016/s0065-230x(08)60331-0. [DOI] [PubMed] [Google Scholar]
  14. Holán V., Mitchison N. A. Allospecific suppression without requirement for participation of Ly 2+ cells. Immunology. 1984 Mar;51(3):469–475. [PMC free article] [PubMed] [Google Scholar]
  15. Macphail S., Stutman O. Suppressor T cells activated in a primary in vitro response to non-major histocompatibility alloantigens. J Exp Med. 1982 Nov 1;156(5):1398–1414. doi: 10.1084/jem.156.5.1398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mills C. D., North R. J. Ly-1+2- suppressor T cells inhibit the expression of passively transferred antitumor immunity by suppressing the generation of cytolytic T cells. Transplantation. 1985 Feb;39(2):202–208. doi: 10.1097/00007890-198502000-00018. [DOI] [PubMed] [Google Scholar]
  17. North R. J., Bursuker I. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med. 1984 May 1;159(5):1295–1311. doi: 10.1084/jem.159.5.1295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. North R. J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982 Apr 1;155(4):1063–1074. doi: 10.1084/jem.155.4.1063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. North R. J. Down-regulation of the antitumor immune response. Adv Cancer Res. 1985;45:1–43. doi: 10.1016/s0065-230x(08)60265-1. [DOI] [PubMed] [Google Scholar]
  20. North R. J. Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells. Cancer Immunol Immunother. 1984;16(3):175–181. doi: 10.1007/BF00205425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. North R. J. Models of adoptive T-cell-mediated regression of established tumors. Contemp Top Immunobiol. 1984;13:243–257. doi: 10.1007/978-1-4757-1445-6_12. [DOI] [PubMed] [Google Scholar]
  22. North R. J. Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells. J Exp Med. 1986 Nov 1;164(5):1652–1666. doi: 10.1084/jem.164.5.1652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rosenberg S. A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986 Sep 19;233(4770):1318–1321. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
  24. Rosenberg S. A., Terry W. D. Passive immunotherapy of cancer in animals and man. Adv Cancer Res. 1977;25:323–388. doi: 10.1016/s0065-230x(08)60637-5. [DOI] [PubMed] [Google Scholar]
  25. Röllinghoff M., Starzinski-Powitz A., Pfizenmaier K., Wagner H. Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J Exp Med. 1977 Feb 1;145(2):455–459. doi: 10.1084/jem.145.2.455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Turk J. L., Parker D. Effect of cyclophosphamide on immunological control mechanisms. Immunol Rev. 1982;65:99–113. doi: 10.1111/j.1600-065x.1982.tb00429.x. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES